Although not entirely precise in terms of the specific date, this menopause predictor is useful for optimizing preventative care for symptoms that disrupt the quality of life. It even has implications for reducing "the risk of diseases and conditions associated with loss of ovarian hormones."
MenoCheck is said to be the "first-ever FDA cleared, clinically validated blood test" of its kind. The menopause predictor is ideal for use by women between the ages of 42 to 62 as they enter the different stages of pre, peri and post menopause. The blood test measures one's levels of Anti-Müllerian Hormone (AMH) to estimate where people are. Moreover, knowledge of this will allow women to make better and more personalized decisions about their health, as well as their method of contraception as they go through menopause.
Menopause-Predicting Blood Tests
The MenoCheck is a Menopause Predictor for Women Between 42 & 62
Trend Themes
1. Menopause Predicting Blood Tests - A trend towards more specific blood tests that can help women predict and manage menopausal symptoms accurately.
2. Personalized Healthcare - With more access to medical data, healthcare can be tailored, and preventive measures taken at an individual level.
3. Preventive Care Innovation - New developments can help design better preventive care, leading to better health outcomes.
Industry Implications
1. Women's Health - As healthcare transcends from curing to preventing diseases, women's health is a hugely untapped market for preventive care innovations.
2. Pharmaceuticals - The pharma industry can develop personalized supplements to manage menopausal symptoms and reduce risks associated with loss of ovarian hormones.
3. Diagnostics - As technologies like AI and machine learning advance, diagnosing medical conditions with more accuracy and speed is bound to disrupt the medical diagnostics industry.